Vireo Growth (VREOF) Depreciation & Amortization (CF) (2020 - 2026)

Vireo Growth's (VREOF) quarterly Depreciation & Amortization (CF) came in at $4.0 million in Q1 2026, up 566.67% year-on-year from $600000.0 in Q1 2025, and down 66.43% quarter-over-quarter from $11.9 million in Q4 2025.

Vireo Growth (VREOF) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends

Vireo Growth has disclosed Depreciation & Amortization (CF) across 7 years of filings, most recently posting $4.0 million for Q1 2026.

  • Depreciation & Amortization (CF) for Q1 2026 came in at $4.0 million, up 566.67% year-over-year; the trailing twelve-month figure through Mar 2026 was $19.5 million (up 679.43% YoY), and the FY2025 annual result was $16.1 million, up 535.04% from the prior year.
  • Depreciation & Amortization (CF) came in at $4.0 million for Q1 2026 at Vireo Growth, down from $11.9 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $11.9 million in Q4 2025 to a low of $600000.0 in Q1 2025.
  • The 5-year median for Depreciation & Amortization (CF) is $776991.0 (2022), against an average of $1.7 million.
  • Across the five-year window, Depreciation & Amortization (CF) slipped 29.08% in 2024 and jumped 1774.66% in 2025, its largest moves.
  • Vireo Growth's Depreciation & Amortization (CF) stood at $889195.0 in 2022, then declined by 26.84% to $650503.0 in 2023, then decreased by 2.29% to $635583.0 in 2024, then surged by 1774.66% to $11.9 million in 2025, then sank by 66.43% to $4.0 million in 2026.
  • The last three Depreciation & Amortization (CF) figures came in at $4.0 million (Q1 2026), $11.9 million (Q4 2025), and $2.3 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Depreciation & Amortization (Qtr)
1 Teva Pharmaceutical Industries 39.72 Bn 35.98 Bn 1.97 Bn 239.00 Mn
2 Zoetis 34.61 Bn 32.67 Bn 1.62 Bn 119.00 Mn
3 United Therapeutics 24.07 Bn 21.91 Bn 648.10 Mn 22.60 Mn
4 Aurora Cannabis 16.98 Bn 16.91 Bn 33.43 Mn -
5 Neurocrine Biosciences 16.64 Bn 15.32 Bn 800.70 Mn 7.20 Mn
6 Elanco Animal Health 12.19 Bn 11.76 Bn 785.00 Mn 172.00 Mn
7 Alkermes 7.37 Bn 6.86 Bn -116.06 Mn 19.43 Mn
8 Hims & Hers Health 6.62 Bn 5.87 Bn 396.79 Mn 21.95 Mn
9 Lantheus Holdings 6.47 Bn 5.97 Bn 230.92 Mn 22.68 Mn
10 Vireo Growth - - 59.30 Mn 4.00 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 4.00 Mn
Mar 31, 2026 4.00 Mn
Dec 31, 2025 11.92 Mn
Dec 31, 2025 11.92 Mn
Sep 30, 2025 2.34 Mn
Sep 30, 2025 2.34 Mn
Jun 30, 2025 1.25 Mn
Jun 30, 2025 1.25 Mn
Mar 31, 2025 600,000.00
Mar 31, 2025 600,000.00
Dec 31, 2024 635,583.00
Dec 31, 2024 635,583.00
Sep 30, 2024 633,586.00
Sep 30, 2024 633,586.00
Jun 30, 2024 633,884.00
Jun 30, 2024 633,884.00
Mar 31, 2024 633,728.00
Mar 31, 2024 633,728.00
Dec 31, 2023 650,503.00
Dec 31, 2023 650,503.00